Limitations of Conventional Imaging in Advanced Prostate Cancer

Welcome to the commentary with Dr. Neal Shore for the Urology Times Peers and Perspectives series. In this episode titled, ‘Limitations of Conventional Imaging in Advanced Prostate Cancer’, Dr. Neal Shore highlights the limitations that have driven the need for more advanced imaging modalities. Over the past two decades, numerous phase 3 clinical trials evaluating therapies across multiple mechanisms of action have relied on conventional imaging techniques, including computed tomography (CT) scans and bone scans, and magnetic resonance imaging (MRI). These modalities formed the foundation for clinical trial endpoints, regulatory approvals, and guideline development across the FDA, EMA, and international regulatory bodies.

Despite their widespread use, conventional imaging approaches have notable limitations in sensitivity, particularly in detecting low-volume disease. Clinicians increasingly recognized that these tools often failed to identify disease in patients with rising prostate-specific antigen (PSA) levels, especially in those with biochemical recurrence or non-metastatic castration-resistant prostate cancer. Key patient populations, including those with negative conventional imaging but rising PSA following surgery, radiation, or androgen deprivation therapy, highlighted a significant unmet clinical need.

The discussion also references early guideline frameworks and index case analyses that emphasized these diagnostic gaps, particularly in patients with rapid PSA doubling times or biochemical relapse without visible metastases. These clinical scenarios underscored the importance of improving imaging sensitivity to better detect and stage disease and guide treatment decisions. Ultimately, the limitations of conventional imaging laid the groundwork for the development and adoption of more advanced imaging technologies aimed at improving detection, staging accuracy, and overall disease management in advanced prostate cancer.

In the next episode, ‘Multidisciplinary Interpretation of PSMA PET in Advanced Prostate Cancer,’ Dr. Neal Shore highlights the multidisciplinary approach required to interpret PSMA PET imaging and apply results to clinical decision-making in advanced prostate cancer. Effective collaboration and clear communication are essential to ensure accurate interpretation and optimal patient care.